Core Points - A class action lawsuit has been filed against Nutex Health Inc. for allegedly making materially false and misleading statements regarding its business operations and financial prospects during the Class Period from August 8, 2024, to August 14, 2025 [8] - The lawsuit claims that Nutex engaged in fraudulent activities through its partnership with HaloMD, leading to unsustainable revenue and overstated financial health [3] - Investors who suffered losses during the specified period are encouraged to contact Bragar Eagel & Squire for legal options [4] Allegation Details - The complaint alleges that Nutex's management made false statements about the company's business and operations, including the success of its arbitration results with HaloMD [3] - It is claimed that Nutex overstated its ability to remediate internal control weaknesses and improperly classified stock-based compensation obligations [3] - The allegations suggest that these misrepresentations increased the risk of delayed financial reporting to the SEC and inflated the company's financial prospects [3] Next Steps - Investors who purchased Nutex shares and experienced losses are invited to reach out to the law firm for more information or to discuss their rights [4] - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 21, 2025 [8]

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) HaloMD was achieving lucrative arbitration results for Nutex by engaging in a ...

DEADLINE: October 27, 2025 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. LifeMD raised its guidance for fiscal year 2025 while ignoring important factors like customer acquisition costs. Based on these facts, LifeMD's public statements were false and materially misleading throughout the class period. If you are a shareholder who suffered a loss, contact us to participate . NEXT STEPS FOR SHAREHOLDERS : Once you register as a shareholder who purchas ...

Core Viewpoint - A class action lawsuit has been filed against Nutex Health Inc. for alleged violations of securities laws, specifically for making false and misleading statements to the market and failing to maintain adequate internal controls [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from August 8, 2024, to August 14, 2025, with a deadline for lead plaintiff appointments set for October 21, 2025 [2]. - The complaint alleges that Nutex was involved in a scheme to defraud insurance companies, leading to materially misleading public statements throughout the class period [2]. Group 2: Shareholder Participation - Shareholders who purchased shares during the specified class period are encouraged to contact the DJS Law Group for potential lead plaintiff appointments, although this is not a requirement for recovery [2][3]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress, with no cost or obligation to participate [3]. Group 3: Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4].

NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Nutex Health Inc. (“Nutex” or the “Company”) (NASDAQ: NUTX) between August 8, 2024 and August 14, 2025, inclusive. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of Nutex Health Inc. (NASDAQ: NUTX)?Did you purchase your shares between August 8, 2024 and August 14, ...

Core Viewpoint - Nutex Health Inc. is facing legal scrutiny due to a class-action lawsuit alleging deceptive billing practices aimed at inflating financial results, involving collaboration with a third-party billing firm, HaloMD [1][2]. Group 1: Allegations and Legal Actions - The lawsuit claims Nutex and HaloMD exploited the insurance arbitration process by submitting thousands of questionable claims, falsely certifying their validity to obtain excessive reimbursements [2]. - A report by activist short-seller Blue Orca Capital accused HaloMD of a fraudulent scheme to extract millions from insurers, leading to significant market fallout and a drop in Nutex's stock price by over 10% [3][4]. - The class-action suit seeks damages for investors misled by Nutex's public disclosures during the alleged misrepresentation period [10]. Group 2: Financial Reporting and Internal Controls - Nutex is accused of misrepresenting its progress in addressing internal control deficiencies, particularly in misclassifying stock-based compensation obligations, which distorted its financial position [5]. - Following a delay in submitting its Form 10-Q due to "non-cash accounting adjustments," Nutex's shares fell by 16.39%, closing at $92.91 [6]. - An Audit Committee found that prior financial statements required restatement due to incorrect classification of obligations related to hospital development [7]. Group 3: Investor Response and Investigations - Hagens Berman is investigating the claims against Nutex, focusing on whether the company's business model relied on questionable arbitration tactics and misleading financial reporting [11]. - The firm encourages investors who suffered losses to submit their claims and is examining the potential for recovery [11].

Nutex Health Conference Summary Company Overview - **Company**: Nutex Health (Ticker: NUTX) - **Industry**: Micro-hospital healthcare services - **CEO**: Tom Vo, with 30 years of healthcare experience, founded Nutex around 2010-2011 [2][3] Core Mission and Vision - **Mission**: To provide accessible, concierge-level care to patients, ensuring they feel well cared for [3][4] - **Vision**: To be the leader in the micro-hospital industry, with a strong demand for services across the U.S. [3][4] Business Model - **Revenue Breakdown**: - 95% from micro-hospital operations - 5% from population health division [4][5] - **Micro-hospital Definition**: Small licensed hospitals (approximately 20,000 square feet) located in high-traffic areas, equipped with emergency rooms, labs, and imaging services [7][9] - **Current Operations**: - 24 locations across 11 states, with plans to reach 27 by the end of 2025 [5][6] - Targeting to open 3-5 new hospitals annually [21][22] Unique Selling Proposition - **Patient Care**: Focus on mid-acuity cases, providing timely care without the long wait times typical of larger hospitals [12][13] - **Local Doctor Alignment**: Establishing partnerships with local physicians to create a referral network, enhancing patient care coordination [6][19] Financial Performance - **Historical Profitability**: Prior to going public in 2022, Nutex had profit margins of 30-40% [24] - **Impact of No Surprises Act**: Revenue dropped by 35% from 2021 to 2022 due to regulatory changes, affecting EBITDA significantly [24][25] - **Recovery Strategy**: Increased patient volume and effective use of arbitration to negotiate fair reimbursements led to recovery of revenue and margins by the end of 2024 [25][26][28] Growth Opportunities - **Hospital Expansion**: Focus on new construction of micro-hospitals, as existing facilities are rare [21][22] - **IPA Development**: Plans to establish Independent Physician Associations around each hospital to enhance care coordination and patient referrals [20][22] - **Acquisition Potential**: Opportunities to acquire existing IPAs to complement hospital operations [22] Investment Highlights - **Management Expertise**: Strong management team with extensive experience in micro-hospitals and healthcare operations [30][33] - **Market Demand**: High demand for services, with requests for new locations across various states [4][30] - **Long-term Strategy**: Commitment to aligning with physicians and providing high-quality patient care as a sustainable business model [31][32] Conclusion - Nutex Health presents a compelling investment opportunity due to its unique micro-hospital model, strong management team, and recovery from regulatory challenges, positioning it for future growth in the healthcare sector [30][33]

Accessibility StatementSkip Navigation BENSALEM, Pa., Sept. 30, 2025 /PRNewswire/ --Â The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Nutex Health Inc. ("Nutex" or the "Company") (NASDAQ:Â NUTX). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NUTEX HEALTH INC. (NUTX), CONTACT THE LAW OFFICES OF HOWARD G. SMITHÂ BEFORE OCTOBER 21, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIE ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Nutex (NUTX) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nutex between August 8, 2024 and August 14, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Braga ...

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Nutex Health Inc. (NASDAQ: NUTX). Shareholders who purchased shares of NUTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/nutex-health-inc-loss-submission-form/?id=169642&from=3 CLASS PERIOD: August 8, ...